A B S T R A C T Female NZB/NZW F1 mice were treated as adults with 5-a-dihydrotestosterone powder packed into subcutaneous implants. Two treatment protocols were followed: (a) 3-mo-old mice received 6 mg of androgen, and (b) 6-mo-old mice were castrated and given 12 mg of androgen. Sham females received empty implants. Mice were followed monthly for survival, for antibodies to DNA and polyadenylic acid, and for renal histopathology.
INTRODUCTION
NZB/NZW F, hybrid mice (B/W)1 mice are considered a laboratory model for systemic lupus erythematosus (1) . Genetic (2) , viral (3) , and immunologic factors (4) are implicated in their disease. Female B/W mice spontaneously develop, after 4 mo of age, a lupus-like disReceived for publicationi 26 July 1978 and in revised form 2 January 1979. 'Abbreviations used in this paper: B/W, (NZB x NZW)F, hybrid mice; PBS, phosphate-buffered saline; Poly A, polyadenylic acid; SLE, systemic lupus ervthematosus; Slp, the sex-limited protein variant of Ss; Ss, the analogue of human C4. order characterized by the formation of antibodies to DNA and to polyadenylic acid (Poly A), the development of immune complex glomerulonephritis and death between 8 and 12 mo of age. Males develop a similar disease later in life.
We reported that prepubertal castration of male B/W mice caused an essentially female pattern of disease with 100% mortalitv at 11 mo (5) . By contrast, prepubertal castration of female B/W mice had no effect on mortality, although it markedly reduced the development of IgG antibodies to Poly A. We subsequently showed that prepubertal castration combined with the administration of either 5-a-dihydrotestosterone or estradiol-17-p8 had profound effects on the autoimmune disease. Mice receiving androgen showed improved survival, reduced anti-nucleic acid antibodies, and less evidence ofglomerulonephritis as determined by light, immunofluorescent, and electron microscopy. By contrast, opposite effects were observed in castrated mice receiving estrogen (6) . These results suggest that sex hormones modulate the expression of autoimmunity in B/W mice, with androgens exerting a protective influence, whereas estrogens accelerate disease process. Similar conclusions have been reached by other investigators (7, 8) . Because these experiments were undertaken in animals less than 1 mo of age, it was important to study the effects of delayed androgen treatment initiated at a time when autoimmtune disease was more developed. We now report the ability of delayed androgen treatment, started at 3 and 6 mo of age, to prolong survival in female B/W mice. An interesting feature of these experiments is the fact that mice are surviving even though there is no significant reduction in levels of anti-DNA antibodies.
METHODS
Mice. B/W mice were from our colony at the University of California Vivarium, San Francisco, Calif., and they were Hormone treatment. Mice were given 5-a-dihydrotestosterone powder packed into silastic tubes, which were then implanted subcutaneously. Control mice received empty implants. This procedure permits a slow release of hormone producing physiologic levels of testosterone for 6-8 mo (6) . Two different treatment protocols were followed. In the first protocol, 43 B/W females received 6 mg of androgen at 3 mo of age. There were 27 B/W females that received sham implants and served as the control group in this experiment. In the second protocol, 19 B/W females were castrated and given 12 mg of estrogen at 6 mo of age. An additional 20 B/W female control mice underwent sham surgery and received an empty implant at 6 mo.
Additional groups of mice were established in the same manner for study of renal histopathology. In this way, there was no necessity to remove mice for examination of the kidneys from the studies measuring survival and autoantibodies.
Oophorectomy was performed through a midline abdominal incision. Ovaries were identified and removed by electrocautery. The incision was closed with 6-0 silk suture material. Experimental animals were distinguished from sham-operated mice by ear-tagging.
Observation. Mice were observed weekly. Mortality in experimental and control groups was tabulated in 2 x were incubated with decomplemented 50-,ul aliquots of each fraction for 30 min at 370C followed by an overnight incubation at 4°C. The antigen-antibody complexes were collected onto cellulose ester filters (Millipore Corp., Bedord, Mass.). The filters were placed in counting vials and covered with 10 ml of Liquifluor-toluene scintillation medium (Liquifluor, New England Nuclear, Boston, Mass.). Radioactivity was determined in a Packard liquid scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill). The radioactive binding profiles revealed clear distribution into 7S and 19S peaks of activity after sucrose gradient fractionation. The radioactivity representing the fractionated 7S and 19S peaks within a single gradient were added and compared for total binding activity. The results are expressed as nanograms radioactive antigen bound per 0.2 ml of serum.
Reproducibility and analysis of data. To establish the reproducibility ofour assay technique and the divergence found in age-matched mice, pooled serum samples from intact, shamoperated and variously treated male and female mice were subjected to sucrose gradient ultracentrifugation and assayed for antibodies to DNA. Ages of these mice ranged from 12 to 36 wk. In all cases, procedures were performed by the same technician, and the radioactive DNA employed was from the same lot. A number of age-matched pooled samples were assayed on the same day, then reassayed 1 mo later. The range of variation from the mean for the total anti-DNA binding in the 19S region was between 1.0 and 14%; in the 7S region variations ranged from 0.2 to 7.1%. A minimum variation of 13% in the immunoglobulin (Ig)M and 8% in the IgG total binding activity from age-and sex-matched, sham-operated controls was required for a result to be considered significant; these values represent 2 SD from the mean.
To determine the biologic variability within each group of mice, subgroups were created by pooling sera in the following way: mice receiving androgen from 3 mo of age were divided into six subgroups, whereas sham mice were divided into three subgroups. In addition, the biologic variability from one mouse to another was determined by comparing levels ofantibodies to DNA and Poly A, and the extent of immune complex Table I . There was an increasing mortality in the sham group, commencing at 6 mo of age. At 11 mo, 89% of the sham-operated animals had died, compared to 26% of the hormone-treated animals (Table I ). In animals treated at 6 mo of age, 80% of the sham-operated controls had died by 11 mo of age, compared to none of the hormone-treated mice (Table II) . In spite of this great difference in mortality between sham and the two androgen-treated groups, there was essentially no difference in the formation of either IgM or IgG antibodies to DNA. The similar age-dependent development ofIgG antibodies to DNA in the sham and androgen-treated groups is illustrated in Table III. There was also a general uniformity between subgroups, and no significant difference between the means of sham and androgen-treated groups (Table III) .
In contrast to anti-DNA, there was a difference in the formation of IgG antibodies to polyadenylic acid between the sham and experimental groups. These antibodies were decreased in the androgen-treated mice compared to the sham animals (Table IV) . A comparison of anti-DNA antibody and mortality is shown for one sham-treated control subgroup of B/W mice in Fig. 1 . There is a rise in anti-DNA from 5 to 7 mo of age associated with a steep increase in mortality from 6 to 8 mo of age. A similar plot for one subgroup receiving androgen from the age of 3 mo shows a striking contrast (Fig. 2) . The high concentrations of anti-DNA present from 6 to 13 mo are not associated with mortality. These animals survive even though they have high levels of IgG antibodies to DNA.
Renal histopathology. Sham and androgen-treated mice were sacrificed at monthly intervals, starting at 6 mo, for examination of renal histopathology. Androgen-treated mice had less evidence ofimmune complex glomerulonephritis when compared to the control group as determined by light, immunofluorescent, and electron microscopy. Sham animals had greater immunofluorescent staining for Ig and C3 in the glomeruli in comparison with either of the androgen-treated groups (Figs. 3 and 4) .
By electron microscopy, sham mice had multiple electron-dense deposits in mesangial areas extending to peripheral portions ofcapillaries (Fig. 5) . The androgen-treated mice had significantly fewer electrondense deposits, with only occasional mesangial areas involved (Fig. 6) .
Comparison of antibodies to nucleic acids and glomerular immunofluorescence in individual mice.
Three sham mice and three mice treated with androgen at 3 mo were studied individually at 9 mo to compare autoantibody levels with glomerular immunoglobulin deposition ( Table V) . The sham animals had large amounts of IgM and IgG antibodies to DNA and Poly A, and three to five plus glomerular immunofluorescence. The treated mice had equally large amounts of antibody to DNA, much less antibody to Poly A, and only one to three plus glomerular immunofluorescence. 
DISCUSSION
The ability of sex hormones to modulate the expression of autoimmunity in B/W mice has been clearly demonstrated (5) (6) (7) (8) . The published studies were performed in young animals before the onset of autoimmune disease. In general, they demonstrate that androgens suppress and estrogens accelerate autoantibody formation, immune complex nephritis, and mortality. They offer an explanation for the female predominance of systemic lupus erythematosus (SLE) and support current pathogenetic concepts which suggest that antibodies to DNA are causally related to the immune complex nephritis.
In our previous studies, prepubertal castration of female B/W mice in the absence of androgen administration had no significant effect on antibodies to DNA or mortality (5) . However, when prepubertal castration was combined with the administration of androgen starting at 2 wk of age, there was a significant reduction in antibodies to DNA, decrease in immune complex glomerular deposits, and prolongation of survival (6) . In these young mice, some effects of castration did not occur if neonatal thymectomy was also performed. These results suggested that sex hormones modulate autoimmunity, at least in part, by thymicDelayed Androgen Treatment Prolongs Survival in Murine Lupus dependent mechanisms capable of regulating auto-delayed to an age just before (3 mo) or during (6 mo) antibody production (6) .
active autoimmune disease. We again observed less im-
In the present studies, androgen treatment was mune complex nephritis and a prolonged survival.
-; ; a ; 6 | . . . \ S The testicular feminization mutant is an X-linked recessive mutation, which renders mice unresponsive to testosterone. The introduction oftesticular feminization mutant into mice expressing Slp totally suppresses its expression (11) . These results indicate a role for androgen in the regulation of expression of the Slp allotype.
A recently characterized mouse serum protein with a specific binding affinity for Ss is also testosterone dependent (1!). Levels of this Ss-binding protein are lower in female than in male mice. Castration of male mice reduces Ss-binding protein, whereas the administration of testosterone increases its expression.
In humans, androgens are therapeutic in hereditary angioneurotic edema, a disease associated with a deficiency of the Cl esterase inhibitors (12) . The administration of androgen or danazol (13), a synthetic weakly androgenic substance, causes Cl inhibitor levels to rise to normal values. There is an accompanying rise in C4, and a marked reduction in clinical attacks.
Androgens probably modulate autoimmunity in B/W mice through more than one mechanism. In the current experiments, in which mice showed less immune complex deposition and prolonged survival in the face of high levels of anti-DNA antibodies, an effect of androgen on the complement system may be responsible. For The therapeutic results achieved with delayed androgen suggest that hormone modulation of autoimmunity might hold promise for the treatment of SLE, even in patients with active disease. Experiments currently underway are designed to determine the best therapeutic approach applicable to human investigation.
